Boehringer Ingelheim Finalizes Acquisition of Amgen's Fremont Facility in the USA

Boehringer Ingelheim Strengthens Global Biopharma Presence.

INGELHEIM, Germany, March 24, 2011 - Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical
development and manufacturing facility in Fremont, California (USA). This
acquisition involves leasing buildings, acquiring physical equipment and
assuming manufacturing processes done at the Fremont site. The
state-of-the-art facility currently employs more than 300 employees and
consists of more than 200,000 square feet for laboratories, manufacturing and
process development suitable for clinical and market supplies. The purchase
agreement was signed in January 2011. The companies agreed not to disclose
details of the purchase price.

(Logo: photos.prnewswire.com/prnh/20110324/CL71469LOGO )

"Presence in Fremont, CA aligns with our growth strategy in several
ways," said Simon Sturge, Corporate Senior Vice President Biopharmaceuticals,
Boehringer Ingelheim GmbH. "The strategic decision to have a state-of-the-art
contract manufacturing facility in the U.S. Bay Area biotechnology cluster
will give Boehringer Ingelheim a greater opportunity to serve current and
future customers. In addition the technological expertise present at Fremont
will complement our goal to further increase Boehringer Ingelheim's world
leading position in the process development and manufacture of
Biopharmaceuticals."

As a fully integrated manufacturing site, the Fremont site complements
the existing capabilities and technology found across the existing Boehringer
Ingelheim biopharma network located in Biberach/Germany and Vienna/Austria.

Boehringer Ingelheim has been a contract manufacturer for Amgen for ten
years and will continue to support Amgen's delivery of safe and effective
medicines to patients around the world. "We look forward to our continued
contract manufacturing partnership with Amgen," said Simon Sturge.

The Boehringer Ingelheim contract manufacturing portfolio includes
sixteen licensed biopharmaceuticals manufactured in globally licensed
multi-product facilities, a growing pipeline of New Biological Entities
(NBEs), and a growth strategy in the Contract Manufacturing Business (CMB).
Boehringer Ingelheim's objective is to remain a leader in Contract
Manufacturing as an industry benchmark for operational excellence including
technical expertise and state-of-the-art technology.

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world's leading companies for contract
development and manufacturing of biopharmaceuticals. All types of services
from mammalian cell line or microbial strain development to final drug
production and global market supply can be delivered within a one-stop-shop
concept. Boehringer Ingelheim has brought 18 molecules to market and has many
years of experience in multiple molecule classes such as monoclonal
antibodies, recombinant proteins, interferons, enzymes, fusion molecules,
novel scaffold proteins and plasmid DNA. For more information please visit
www.biopharma-cmo.com.

The Boehringer Ingelheim group is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates
globally with 142 affiliates in 50 countries and more than 41,500 employees.
For over 125 years, the family-owned company has been committed to
researching, developing, manufacturing and marketing novel products of high
therapeutic value for human and veterinary medicine. In 2009, Boehringer
Ingelheim posted net sales of 12.7 billion euro while spending 21% of net
sales in its largest business segment Prescription Medicines on research and
development. For more information please visit www.boehringer-ingelheim.com.

U.S. Media Inquiries: Jason Kurtz, Communications & PR, Boehringer Ingelheim Ben Venue Laboratories, Inc., +1-440-201-3668, Jason.Kurtz at boehringer-ingelheim.com; Outside the U.S.: Heidrun Thoma, Corporate Communications, Germany, Boehringer Ingelheim GmbH, +49-6132-77-3966, Heidrun.Thoma at boehringer-ingelheim.com; Twitter: www.twitter.com/boehringer